Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapyModel, vector, and radionuclide selection

被引：26

作者：

Carter, Lukas M. ^{[1
]}

Poty, Sophie ^{[1
]}

Sharma, Sai Kiran ^{[1
]}

Lewis, Jason S. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, Dept Radiol, New York, NY USA

[4] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Radiochem & Mol Imaging Probes Core, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS | 2018年 / 61卷 / 09期

关键词：

antibody; therapy; imaging; radionuclide; animal model; HUMAN MONOCLONAL-ANTIBODIES; FULLY HUMAN-ANTIBODIES; PRETARGETED RADIOIMMUNOTHERAPY; RADIOLABELED ANTIBODIES; MEMBRANE ANTIGEN; XENOGRAFT MODELS; PROSTATE-CANCER; NEXT-GENERATION; MOUSE MODELS; IMMUNO-PET;

D O I：

10.1002/jlcr.3612

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally exquisitely specific and selective vectors, enabling recognition of individual cancer-associated molecular phenotypes against a complex and dynamic biomolecular background. Complementary alignment of these advantages with unique properties of radionuclides is a defining paradigm in both radioimmunoimaging and radioimmunotherapy, which remain some of the most adept and promising tools for cancer diagnosis and treatment. This review discusses how translational potency can be maximized through rational selection of antibody-nuclide couples for radioimmunoimaging/therapy in preclinical models.

引用

页码：611 / 635

页数：25

共 141 条

[1] Production of terbium-152 by heavy ion reactions and proton induced spallation [J].

Allen, BJ ;

Goozee, G ;

Sarkar, S ;

Beyer, G ;

Morel, C ;

Byrne, AP .

APPLIED RADIATION AND ISOTOPES, 2001, 54 (01) :53-58

[2] Humanization of antibodies [J].

Almagro, Juan C. ;

Fransson, Johan .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :1619-1633

[3] Pretargeted Imaging and Therapy [J].

Altai, Mohamed ;

Membreno, Rosemery ;

Cook, Brendon ;

Tolmachev, Vladimir ;

Zeglis, Brian M. .

JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (10) :1553-1559

[4] Examining the utility of patient-derived xenograft mouse models [J].

Aparicio, Samuel ;

Hidalgo, Manuel ;

Kung, Andrew L. .

NATURE REVIEWS CANCER, 2015, 15 (05) :311-316

[5] Generalized PSF modeling for optimized quantitation in PET imaging [J].

Ashrafinia, Saeed ;

Mohy-ud-Din, Hassan ;

Karakatsanis, Nicolas A. ;

Jha, Abhinav K. ;

Casey, Michael E. ;

Kadrmas, Dan J. ;

Rahmim, Arman .

PHYSICS IN MEDICINE AND BIOLOGY, 2017, 62 (12) :5149-5179

[6] Molecular Pathways: Targeted α-Particle Radiation Therapy [J].

Baidoo, Kwamena E. ;

Yong, Kwon ;

Brechbiel, Martin W. .

CLINICAL CANCER RESEARCH, 2013, 19 (03) :530-537

[7]

Balkin ER, 2014, CANCER RES, V74, P5864

[8]

Behr TM, 1998, INT J CANCER, V77, P787, DOI 10.1002/(SICI)1097-0215(19980831)77:5<787::AID-IJC19>3.0.CO

[9]

2-Z

[10]

Bethe H, 1930, ANN PHYS-BERLIN, V5, P325

← 1 2 3 4 5 6 7 8 9 10 →